Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune-mediated liver injury

Abstract

Primary sclerosing cholangitis (PSC) is a variably progressive, fibrosis-causing autoimmune disorder of the intra- and extra-hepatic bile ducts of unclear etiology. PSC is commonly (in 60-90% of cases) associated with an inflammatory bowel disease (IBD) like PSC-IBD, and less commonly with an autoimmune hepatitis (AIH) like PSC-AIH or AIH-overlap disorder. Hepatologists and Gastroenterologists often consider these combined conditions as distinctly different from the classical forms in isolation. Here, we review recent epidemiologic observations and highlight that PSC-IBD and PSC-AIH overlap appear to represent aspects of a common PSC clinico-pathological pathway and manifest in an age-of-presentation dependent manner. Particularly from the pediatric experience, we hypothesize that all cases of PSC likely originate from a complex “Early PSC”-“IBD”-“AIH” overlap in which PSC defines the uniquely and variably associated “AIH” and “IBD” components along an individualized lifetime continuum. We speculate that a distinctly unique, ‘diverticular autoimmunity’ against the embryonic cecal- and hepatic diverticulum derived tissues may be the origin of this combined syndrome, where “AIH” and “IBD” variably commence then variably fade while PSC progresses with age. Our hypothesis provides an explanation for the age-dependent variation in the presentation and progression of PSC. This is critical for the optimal targeting of studies into PSC etiopathogenesis and emphasizes the concept of a “developmental window of opportunity for therapeutic mitigation” in what is currently recognized as an irreversible disease process. The discovery of such a window would be critically important for the targeting of interventions, both administration of current therapies and therapeutic trial planning.